Inova Labs receives CE Mark Approval for the LifeChoice® Portable Oxygen Concentrator System - Gilde Healthcare

Menu
Menu
Home

Inova Labs receives CE Mark Approval for the LifeChoice® Portable Oxygen Concentrator System

December 1, 2011

New Technology enables COPD patients to experience true portability while maintaining appropriate oxygen concentration levels during both day and night

Austin, TX – Inova Labs, a privately held medical device company focused on developing innovative products for the Chronic Obstructive Pulmonary Disease (COPD) Market, announced today that it has received CE Mark approval to begin marketing the LifeChoice® Portable Oxygen Concentrator System in Europe.

“This is a major milestone for our Company and for COPD patients who are on Long Term Oxygen Therapy,” said John Rush, CEO of Inova Labs.   “The LifeChoice® technology allows patients to continue to live their daily lives with minimal disruption despite the advanced stage of their COPD disease.”

The Company is currently in discussions with potential partners in Europe and expects to begin marketing the LifeChoice® Technology in the region in early 2012.

– Ends –

About Inova Labs

Inova Labs is an Austin, Texas based medical device company which develops and commercializes innovative products for the COPD market.  The company is currently marketing the LifeChoice® Portable Oxygen Concentrator System, which is the lightest and smallest oxygen concentrator on the market with FDA approval for continuous use by patients.   LifeChoice® delivers oxygen to the COPD patient using a proprietary “Pulse Wave” technology, which insures that the patient receives maximum benefit from the oxygen produced.  LifeChoice® also offers “Auto Mode” technology which enables the patient to automatically receive the prescribed oxygen dose during periods of activity as well as sleep.  The product is approved by FAA for air travel and is manufactured under strict ISO certification guidelines.

More news

Gilde Healthcare acquires MEG, a group of specialized providers of medical aids, from Harald Quandt Industriebeteiligungen (“HQIB”)

Gilde Healthcare’s private equity fund today announced the acquisition of MEG Medical Equipment GmbH (“MEG”), a provider of high-quality medical aids for treatment and prevention of decubitus and other skin damages resulting from extended immobility,...
November 14, 2025

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
October 17, 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
October 15, 2025